Joseph M. Miller - 09 Oct 2026 Form 4 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: LBRX
Reported as of: 09 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Oct 2026, 16:10:08 UTC
Prior SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Panoff, Attorney-in-Fact

Filing notes and source

Key filing fact

Joseph M. Miller filed Form 4 for LB PHARMACEUTICALS INC (LBRX) on 13 Oct 2026.

Key facts

This page summarizes Joseph M. Miller's Form 4 filing for LB PHARMACEUTICALS INC (LBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Oct 2026, 16:10.

Change

Previous filing in this sequence was filed on 14 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001746372 Primary reporting owner

Miller Joseph M

Relationship: Chief Financial Officer
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Marc Panoff, Attorney-in-Fact
Signature date: 13 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX transaction Derivative

Emplopyee Stock Option (Right to Buy)

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 09 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $37.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One fourth (1/4th) of the shares subject to the option award shall vest on September 2, 2027, and the remaining shares subject to the option award shall vest over the following three years on a monthly basis on the last day of the month commencing on September 30, 2027, subject to the Reporting Person's continuous service through such vesting date.